Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Karuna Therapeutics, Inc.    KRTX

KARUNA THERAPEUTICS, INC.

(KRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
107.59(c) 108.4(c) 102.7(c) 100.85(c) 99(c) Last
104 063 102 490 145 866 103 780 103 987 Volume
+0.42% +0.75% -5.26% -1.80% -1.83% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -67,9 M - -
Net cash position 2020 171 M - -
P/E ratio 2020 -38,6x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -110 M - -
Net cash position 2021 212 M - -
P/E ratio 2021 -24,7x
Yield 2021 -
Capitalization 2 654 M 2 654 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 19
Free-Float 85,5%
More Financials
Company
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in... 
More about the company
Notations Surperformance© of Karuna Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about KARUNA THERAPEUTICS, INC.
01/07KARUNA THERAPEUTICS : to Participate in the ICR Conference 2021
BU
01/05KARUNA THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confe..
BU
2020KARUNA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial..
AQ
2020KARUNA THERAPEUTICS : Appoints Denice Torres, J.D., to its Board of Directors
BU
2020KARUNA THERAPEUTICS : EMERGENT-1 American College of Neuropsychopharmacology (AC..
PU
2020KARUNA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial..
AQ
2020KARUNA THERAPEUTICS : Appoints David Wheadon, M.D., to Its Board of Directors
BU
2020INSIDER TRENDS : Insider 90-Day Selling Trend Extended at County Bancorp
MT
2020Maxim Group Starts Karuna Therapeutics at Buy with $150 Price Target
MT
2020KARUNA THERAPEUTICS : to Present at the Stifel 2020 Virtual Healthcare Conferenc..
AQ
2020KARUNA THERAPEUTICS : to Present at the Stifel 2020 Virtual Healthcare Conferenc..
BU
2020Wedbush Adjusts Price Target on Karuna Therapeutics to $122 From $121, Keeps ..
MT
2020Karuna Therapeutics Q3 Loss Widens. Operating Expenses Grow
MT
2020KARUNA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
2020KARUNA THERAPEUTICS : Corporate Presentation – November 2020
PU
More news
News in other languages on KARUNA THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on KARUNA THERAPEUTICS, INC.
More recommendations
Chart KARUNA THERAPEUTICS, INC.
Duration : Period :
Karuna Therapeutics, Inc. Technical Analysis Chart | KRTX | US48576A1007 | MarketScreener
Technical analysis trends KARUNA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 130,08 $
Last Close Price 99,00 $
Spread / Highest target 64,6%
Spread / Average Target 31,4%
Spread / Lowest Target 16,2%
EPS Revisions
Managers and Directors
NameTitle
Steven Marc Paul Chairman, President & Chief Executive Officer
Andrew Miller Chief Operating Officer
Troy A. Ignelzi Chief Financial Officer & Secretary
Stephen Brannan Chief Medical Officer
Inder Kaul Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
KARUNA THERAPEUTICS, INC.-2.55%2 654
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458